These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Muenzer J Mol Genet Metab; 2014 Feb; 111(2):63-72. PubMed ID: 24388732 [TBL] [Abstract][Full Text] [Related]
23. Changes in cellular processes occurring in mucopolysaccharidoses as underestimated pathomechanisms of these diseases. Gaffke L; Pierzynowska K; Podlacha M; Brokowska J; Węgrzyn G Cell Biol Int; 2021 Mar; 45(3):498-506. PubMed ID: 31855304 [TBL] [Abstract][Full Text] [Related]
24. Current and Emerging Therapies for Mucopolysaccharidoses. Lagler FB Handb Exp Pharmacol; 2020; 261():39-56. PubMed ID: 31451968 [TBL] [Abstract][Full Text] [Related]
25. The Inflammation in the Cytopathology of Patients With Mucopolysaccharidoses- Immunomodulatory Drugs as an Approach to Therapy. Wiesinger AM; Bigger B; Giugliani R; Scarpa M; Moser T; Lampe C; Kampmann C; Lagler FB Front Pharmacol; 2022; 13():863667. PubMed ID: 35645812 [TBL] [Abstract][Full Text] [Related]
26. Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration. Lau AA; Hemsley KM J Mol Med (Berl); 2017 Oct; 95(10):1043-1052. PubMed ID: 28660346 [TBL] [Abstract][Full Text] [Related]
27. The Role of Dimethyl Sulfoxide (DMSO) in Gene Expression Modulation and Glycosaminoglycan Metabolism in Lysosomal Storage Disorders on an Example of Mucopolysaccharidosis. Moskot M; Jakóbkiewicz-Banecka J; Kloska A; Piotrowska E; Narajczyk M; Gabig-Cimińska M Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646511 [TBL] [Abstract][Full Text] [Related]
31. Mucopolysaccharidoses Differential Diagnosis by Mass Spectrometry-Based Analysis of Urine Free Glycosaminoglycans-A Diagnostic Prediction Model. D'Avanzo F; Zanetti A; Dardis A; Scarpa M; Volpi N; Gatto F; Tomanin R Biomolecules; 2023 Mar; 13(3):. PubMed ID: 36979466 [TBL] [Abstract][Full Text] [Related]
32. Emerging drugs for the treatment of mucopolysaccharidoses. Giugliani R; Federhen A; Vairo F; Vanzella C; Pasqualim G; da Silva LM; Giugliani L; de Boer AP; de Souza CF; Matte U; Baldo G Expert Opin Emerg Drugs; 2016; 21(1):9-26. PubMed ID: 26751109 [TBL] [Abstract][Full Text] [Related]
33. Protein aggregation and autophagy dysfunction: new lessons from mucopolysaccharidoses. Monaco A; Fraldi A Autophagy; 2021 Nov; 17(11):3875-3876. PubMed ID: 34407725 [TBL] [Abstract][Full Text] [Related]
34. Transcriptomic Changes Related to Cellular Processes with Particular Emphasis on Cell Activation in Lysosomal Storage Diseases from the Group of Mucopolysaccharidoses. Rintz E; Gaffke L; Podlacha M; Brokowska J; Cyske Z; Węgrzyn G; Pierzynowska K Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32366041 [TBL] [Abstract][Full Text] [Related]
35. Treatment of brain disease in the mucopolysaccharidoses. Scarpa M; Orchard PJ; Schulz A; Dickson PI; Haskins ME; Escolar ML; Giugliani R Mol Genet Metab; 2017 Dec; 122S():25-34. PubMed ID: 29153844 [TBL] [Abstract][Full Text] [Related]
40. A general model for genetic regulation of turnover of glycosaminoglycans suggests a possible procedure for prediction of severity and clinical progress of mucopolysaccharidoses. Wegrzyn G; Wegrzyn A; Tylki-Szymańska A Med Hypotheses; 2004; 62(6):986-92. PubMed ID: 15142662 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]